# Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

> **NCT07050511** · PHASE1 · COMPLETED · sponsor: **Generate Biomedicines** · enrollment: 51 (actual)

## Conditions studied

- SARS CoV-2

## Interventions

- **DRUG:** GB-0669
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07050511
- **Lead sponsor:** Generate Biomedicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-18
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050511, "Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07050511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*